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Abstract 
We report a rare case of extrapulmonary small cell carcinoma arising in the palatine tonsil 
treated by combined chemotherapy with irinotecan/cisplatin following irradiation therapy. 
This chemotherapy regimen was recently found to be effective for small cell lung carcinoma. 
Our case is the first report of combined irinotecan/cisplatin chemotherapy to treat 
extrapulmonary small cell carcinoma of the oropharynx. 
 
Introduction 
Small cell carcinoma is a malignancy that occurs mainly in the lung, and primary 
lesions in the head and neck are very rare. Extrapulmonary small cell carcinoma 
(EPSCC) shows a fair response to either chemotherapy or chemoradiotherapy, similar 
to small cell lung carcinoma (SCLC); however, poor prognosis has been reported due to 
its high metastatic potential. Irinotecan hydrochloride (CPT-11), a topoisomerase I 
inhibitor, has been reported to be effective against SCLC [1]. Here, we report a rare case 
of EPSCC of the tonsil, treated with CPT-11 and cisplatin (CDDP), which is the recent 
treatment protocol for SCLC. The present case represents the first report of CPT-11 
usage for EPSCC of the oropharynx. Our case suggests that CPT-11 and CDDP may 
become an effective treatment option for EPSCC of the oropharynx. Case Rep Oncol 2011;4:587–591 
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Case Report 
A 65-year-old male presented to our hospital complaining of sore throat for 2 weeks. He smoked 
heavily (70 cigarettes per day for 40 years) and was also a long-time alcohol drinker. His medical 
history included diabetes mellitus and aortic stenosis. Physical examination revealed an ulcerated 
mass in the left palatine tonsil and multiple swollen left neck lymph nodes. Computed tomography 
(CT) scans of the head and neck revealed a well-defined, 3.2 × 3 cm mass in the left tonsil with 
multiple left cervical lymph node involvement. 
A biopsy from the tonsillar mass was performed. Hematoxylin and eosin-stained sections revealed 
nests of monotonous, small, round carcinoma cells with scant cytoplasm and frequent mitotic figures 
in the subepithelial tissue (fig. 1). Immunohistochemically, the tumor cells were positive for neural 
cell adhesion molecule (CD56), synaptophysin, chromogranin, cytokeratin, and epithelial membrane 
antigen; the cells were negative for S-100 protein, HMB-45, leukocyte common antigen, and thyroid 
transcription factor-1 (fig. 2a, b). The MIB-1 labeling index was 88.5% (fig. 2c). These findings 
indicated small cell carcinoma. 
To differentiate primary small cell carcinoma from a metastatic SCLC, a chest CT was performed, 
revealing no lesions. In addition, systemic workup, such as of the brain, as well as abdominal CT and 
FDG-PET showed negative findings for distant metastasis. The tumor was diagnosed as oropharyngeal 
cancer, T2N2bM0 (TNM classification, UICC, 2002). 
Because cardiac echo revealed severe aortic stenosis and moderate aortic regurgitation, the 
patient received aortic valve replacement before treating the EPSCC of the tonsil. The tonsillar mass 
then grew to 4.6 × 3.8 cm, and the left neck lymph nodes also progressed (fig. 3); however, distant 
metastases were not recognized. 
One month after the cardiac operation, he underwent radiotherapy of the tonsil and the bilateral 
cervical area with a dosage of 65.4 Gy in 35 fractions. He was also planned to receive three courses of 
chemotherapy with a regimen including CPT-11 (60 mg/m2, days 1 and 15) and CDDP (30 mg/m2, 
days 1 and 15) at 4-week intervals. Because severe thrombocytopenia occurred after the first course 
of chemotherapy, the second and third courses were performed with reduced doses of CPT-11 (48 
mg/m2, days 1 and 15) and CDDP (24 mg/m2, days 1 and 15) at 3-week intervals. After 
chemo/radiotherapy, complete remission of the tumor was achieved. 
Recurrent disease appeared in his liver 9 months after chemotherapy. The patient died from liver 
failure 2 years after the initial presentation. 
Discussion 
EPSCC compromises only 2.5–4% of all small cell carcinomas and is commonly found 
in the esophagus, colon, pancreas, uterus, and breast. It reveals a fair response to either 
chemotherapy or chemoradiotherapy but exhibits a poor prognosis. In general, the 
clinical course of EPSCC is known to be aggressive because of frequent metastases and 
recurrences. Therefore, it should be considered a ‘systemic’ disease from the onset of 
treatment, even when no distant metastasis is recognized at the first medical 
examination. 
In the head and neck region, the most common sites are the larynx, nose, and 
paranasal sinuses, and the major salivary glands [2]. Primary small cell carcinoma of 
the tonsil is rare; only 11 cases have been reported [3–9]. The prognosis of patients 
with EPSCC of the tonsil has been poor, as 6 of those 11 patients died from the disease 
mainly due to systemic metastasis. 
When a diagnosis of EPSCC arising in the head and neck region is made, the patient 
should be evaluated first to determine whether the disease is a primary or metastatic Case Rep Oncol 2011;4:587–591 
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cancer. Primary SCLC is rarely occult because it is aggressive and fast-growing. In our 
case, chest and abdominal CT and FDG-PET revealed no other lesions, and the tonsillar 
mass was determined to be the primary lesion. 
The histopathological aspects of EPSCC include round, oval- to spindle-shaped small 
cells with dense chromatin, absence of nucleoli, and inconspicuous cytoplasm. Mitosis, 
necrosis, apoptosis, and lymphatic, vascular, and perineural invasion are common. 
Immunohistochemical staining for neuroendocrine markers, including chromogranin A, 
synaptophysin, and CD56, is usually positive. In this case, histologic features and 
immunoreactivity for neuroendocrine markers were suggestive of EPSCC. 
Although the treatment of this tumor has not been defined clearly, it can require 
surgical excision of the localized tumor, radiation therapy to the primary site, multiple-
drug chemotherapy, or a combination of these modalities. The chemotherapeutic 
regimens for EPSCC are similar to those employed in SCLC. Platinum-based 
chemotherapy, such as the use of etoposide (VP-16) and CDDP, has been recognized as 
the standard regimen for EPSCC [2]. Recently, CPT-11 combined with CDDP was found 
to be more effective than VP-16 and CDDP [1]. Two cases of chemotherapy using CPT-
11 and CDDP have been reported for EPSCC arising in the head and neck region: one in 
the larynx and the other in the nasal cavity [10, 11]. Both cases achieved long-term 
remission. In our case, radiation therapy to primary and locoregional sites followed by 
immediate chemotherapy with CPT-11/CDDP resulted in complete remission of the 
tumor, although the patient later died of liver metastasis. 
An effective systemic chemotherapy should be established to regulate this highly 
metastatic disease. 
Conclusion 
In this report, we describe a case of small cell carcinoma of the tonsil treated by 
combined chemotherapy with CPT-11/CDDP after radiotherapy. This is the first report 
on the use of combined CPT-11/CDDP chemotherapy in small cell carcinoma of the 
oropharynx.  
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Fig. 1. Histologic appearance of the tumor. a The tumor was arranged in nests and grew in the 
subepithelial tissue. b The tumor had scant cytoplasm, and mitotic figures were frequently seen. 
 
 
 
Fig. 2. Immunohistochemical staining of the tumor. a Staining of cell membrane for CD56. 
b Cytoplasmic staining for synaptophysin. c Tumor staining reveals a high MIB-1 labeling index of 
88.5%. 
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Fig. 3. Computed tomography. a Tumor of the left palatine tonsil with ulceration (arrows). 
b Swelling of the left cervical lymph nodes (arrows). 
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